Ugrás a tartalomra
Merck
Összes fotó(2)

Fontos dokumentumok

View All Documentation

911658

Sigma-Aldrich

Pomalidomide-C3-NH2 hydrochloride

≥95%

Szinonimák:

4-((3-Aminopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride, Crosslinker−E3 ligase ligand conjugate, Pomalidomide conjugate, Protein degrader building block for PROTAC® research, Template for synthesis of targeted protein degrader

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(2)

About This Item

Tapasztalati képlet (Hill-képlet):
C16H18N4O4 · xHCl
Molekulatömeg:
330.34 (free base basis)
MDL-szám:
MFCD31729296
UNSPSC kód:
12352101
NACRES:
NA.22

ligand

pomalidomide

Teszt

≥95%

Forma

powder

reakcióalkalmasság

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

funkcionális csoport

amine

tárolási hőmérséklet

2-8°C

SMILES string

O=C(C(CC1)N(C2=O)C(C3=C2C=CC=C3NCCCN)=O)NC1=O.Cl

Alkalmazás

Protein degrader building block Pomalidomide-C3-NH2 hydrochloride enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting ligand and an alkyl-chain crosslinker with pendant amine for reactivity with an acid on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a terminal amine, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Egyéb megjegyzések

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Jogi információk

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

kapcsolódó termék

Product No.
Leírás
Árazás

901490

(S,R,S)-AHPC hydrochloride, ≥97%

901487

(S,S,S)-AHPC hydrochloride, ≥97%

901488

(S,R,S)-AHPC-PEG2-NH2 hydrochloride, ≥95%

901493

(S,R,S)-AHPC-PEG1-NH2 hydrochloride, ≥95%

901494

N-Methylated pomalidomide, ≥98%

901495

Pomalidomide-PEG3-NH2 hydrochloride, ≥95%

901496

Pomalidomide-C6-CO2H, ≥98%

901500

Pomalidomide-C3-CO2H, ≥95%

901503

(S,R,S)-AHPC-PEG1-Alkyne, ≥95%

901511

(S,R,S)-AHPC-PEG3-NH2 hydrochloride, ≥95%

901504

Pomalidomide-PEG3-CO2H, ≥95%

901517

(S,R,S)-AHPC-PEG2-Alkyne, ≥95%

901516

Pomalidomide-PEG1-NH2 hydrochloride, ≥95%

901513

Pomalidomide-PEG2-NH2 hydrochloride, ≥95%

901523

Pomalidomide-PEG1-Alkyne, ≥98%

901533

(S,R,S)-AHPC-PEG3-Alkyne, ≥95%

901534

(S,R,S)-AHPC-C6-CO2H hydrochloride

901531

Pomalidomide-PEG3-Alkyne, ≥95%

901529

Pomalidomide-PEG2-Alkyne, ≥95%

901527

Pomalidomide-PEG1-CO2H, ≥95%

901526

Pomalidomide-PEG2-CO2H, 95%

901525

Pomalidomide-C9-CO2H, ≥95%

901558

Lenalidomide, ≥95%

901835

Pomalidomide-PEG6-Alkyne

901834

Pomalidomide-PEG5-Alkyne, ≥95%

901833

Pomalidomide-PEG4-Alkyne

901832

Pomalidomide-PEG6-NH2 hydrochloride, ≥98%

901831

Pomalidomide-PEG5-NH2 hydrochloride

901830

Pomalidomide-PEG4-NH2 hydrochloride, ≥95%

901829

Pomalidomide-PEG6-CO2H

901828

Pomalidomide-PEG5-CO2H, ≥95%

901824

Pomalidomide-PEG4-CO2H

901860

(S,R,S)-AHPC-PEG6-NH2 hydrochloride, ≥95%

901855

(S,R,S)-AHPC-PEG5-Alkyne

901851

(S,R,S)-AHPC-PEG4-Alkyne

901850

(S,R,S)-AHPC-PEG5-NH2 hydrochloride

901848

(S,R,S)-AHPC-PEG4-NH2 hydrochloride, ≥95%

901873

(S,R,S)-AHPC-PEG6-Alkyne

903434

Pomalidomide-PEG6-butyl azide, ≥95%

903442

Pomalidomide-PEG6-butyl iodide, ≥95%

903833

Pomalidomide-PEG2-azide

903825

Pomalidomide-PEG1-azide

903957

(S,R,S)-AHPC-PEG1-azide

904651

(S,R,S)-AHPC-PEG3-azide, ≥95%

904724

Pomalidomide-PEG2-butyl iodide, ≥95%

904708

Pomalidomide-C6-PEG3-butyl iodide, ≥95%

904678

Pomalidomide-PEG3-azide

904686

Pomalidomide-C6-PEG3-butyl azide, ≥95%

904813

(S,R,S)-AHPC-PEG2-azide

904821

(S,R,S)-AHPC-C6-PEG3-butyl azide, ≥95%

904880

Pomalidomide-C6-PEG1-C3-PEG1-butyl azide, ≥95%

904872

Pomalidomide-PEG2-butyl azide, ≥95%

904864

(S,R,S)-AHPC-PEG6-butyl azide, ≥95%

905178

(S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl azide, ≥95%

905275

(S,R,S)-AHPC-PEG6-butyl amine hydrochloride, ≥95%

905216

(S,R,S)-AHPC-PEG2-butyl azide, ≥95%

905232

(S,R,S)-AHPC-C6-PEG3-butyl amine hydrochloride, ≥95%

905224

Pomalidomide-PEG6-butyl amine hydrochloride, ≥95%

905208

Pomalidomide-C6-PEG3-butyl amine hydrochloride, ≥98%

905399

(S,R,S)-AHPC-PEG2-butyl chloride

905380

(S,R,S)-AHPC-C6-PEG3-butyl chloride, ≥95%

905402

(S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl chloride, 95%

906050

Pomalidomide-C6-PEG1-C3-PEG1-butyl iodide, ≥95%

906123

(S,R,S)-AHPC-PEG2-butyl amine hydrochloride

907677

(S,R,S)-AHPC-PEG6-butyl chloride

909351

(S,R,S)-AHPC-PEG5-azide, ≥98%

909378

(S,R,S)-AHPC-PEG6-Azide, ≥95%

909386

Pomalidomide-PEG4-Azide, ≥95%

909394

Pomalidomide-PEG5-azide, ≥95%

909408

Pomalidomide-PEG6-azide, ≥95%

909416

Fluorinated VHL spy molecule 1

909432

Fluorinated VHL Spy Molecule 2, ≥98%

909440

Fluorinated VHL spy molecule 3, ≥95%

909459

Fluorinated VHL Spy Molecule 4, ≥98%

909262

(S,R,S)-AHPC-PEG4-Azide, ≥95%

910449

Pomalidomide-PEG2-butyl CO2H, ≥95%

910619

Pomalidomide-PEG6-butyl alkyne, ≥95%

910597

(S,R,S)-AHPC-PEG6-butyl alkyne, ≥95%

910538

(S,R,S)-AHPC-PEG2-butyl alkyne, ≥95%

910511

Pomalidomide-C6-PEG3-butyl alkyne, ≥95.0%

910503

Pomalidomide-PEG2-butyl alkyne, ≥95%

910481

Pomalidomide-PEG6-butyl CO2H, ≥95%

911003

Pomalidomide-PEG2-butyl amine hydrochloride, ≥95%

911720

C5 Lenalidomide-C9-NH2 hydrochloride, ≥95%

911712

C5 Lenalidomine-C6-NH2 hydrochloride, ≥95%

911755

C5 Lenalidomide-PEG5-NH2 hydrochloride

911704

C5 Lenalidomine-C3-NH2 hydrochloride, ≥95%

911739

C5 Lenalidomide-PEG1-NH2 hydrochloride, ≥95%

911747

C5 Lenalidomide-PEG3-NH2 hydrochloride, ≥95%

917052

(S,R,S)-AHPC-C3-NH2 hydrochloride, ≥95%

917559

(S,R,S)-AHPC-C6-NH2 hydrochloride, ≥95%

918350

C5 Lenalidomide-alkyne-piperidine hydrochloride, ≥95%

919403

CCW16-C4-BocNH, 95%

920746

Pomalidomide-benzyl-piperazine hydrochloride

920754

C5 Lenalidomide-benzyl-piperazine hydrochloride

920789

Pomalidomide-pyridine-PEG1-piperazine hydrochloride

920797

C5 Lenalidomide-pyridine-PEG1-piperazine hydrochloride, ≥95%

920800

C5 Lenalidomide-methylamino-PEG1-NH2 hydrochloride, ≥95%

921300

C5 Lenalidomide-pyrimidine-piperazine-PEG1-NH2 hydrochloride, ≥95%

921327

C5 Lenalidomide-PEG6-Butyl NH2 hydrochloride, ≥95%

924202

5-Amino-Thalidomide, ≥95%

Piktogramok

Health hazard
GHS08

Figyelmeztetés

Danger

Figyelmeztető mondatok

H360D

Óvintézkedésre vonatkozó mondatok

P201 - P202 - P280 - P308 + P313 - P405 - P501

Veszélyességi osztályok

Repr. 1B

Tárolási osztály kódja

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number
0000215235
0000157121
0000174162
0000193520

Nem találja a megfelelő verziót?

Ha egy adott verzióra van szüksége, a tétel- vagy cikkszám alapján rákereshet egy adott tanúsítványra.

COA keresése

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Yangbing Li et al.
Journal of medicinal chemistry, 62(2), 448-466 (2018-12-12)
Human murine double minute 2 (MDM2) protein is a primary endogenous cellular inhibitor of the tumor suppressor p53 and has been pursued as an attractive cancer therapeutic target. Several potent, nonpeptide, small-molecule inhibitors of MDM2 are currently in clinical development.
Xing Qiu et al.
Organic letters, 21(10), 3838-3841 (2019-05-09)
An organic base-promoted chemoselective alkylation of lenalidomide with different halides was developed, which offers a novel approach to a highly functionalized lenalidomide-based PROTAC library under mild reaction conditions. DIPEA was found to act as an efficient base to trigger facile
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is

Cikkek

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással